BioSpace News Archive

Interim analysis from VISIBLE OLE study showed long-term findings consistent with the known safety profile of vedolizumab with maintained rates of clinical remission and corticosteroid-free clinical remission

Transparency Market Research delivers key insights on the global digital dose inhalers market. In terms of revenue, the global digital dose inhalers market is estimated to expand at a CAGR of ~ 10% during the forecast period, owing to numerous factors, regarding which, TMR offers thorough insights and forecasts in the digital dose inhalers market report.

The global digital intraoral sensors and consumables market is expected to show stupendous growth curve during the forecast period of 2020 to 2030.

Meditation refers to the ancient practice of wellness that emphasizes on training on compassion, attention, and awareness.

Plantar fasciitis has emerged as a persistent kind of repetitive strain injury that afflicts runners, hikers, and walkers, and also nearly everyone who stands for a living, such as cashiers for instance, especially on hard surfaces.

Growing worldwide population living with numerous disease conditions is projected to stimulate fabulous demand opportunities in the US therapeutic plasma exchange market during 2019–2029.

Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, announce that the European Patent Office has granted European Patent no 3293201.

Masimo announced the findings of an abstract recently presented at ANESTHESIOLOGY® 2020, the Annual Meeting of the American Society of Anesthesiologists.

Clinical Laserthermia Systems and Otto-von-Guericke-University Magdeburg, Medical faculty are entering into an agreement regarding an Investigator Initiated Trial targeting MRI-Ultrasound, fusion-guided focal laser ablation treatment of prostate cancer, up to Gleason 7a, using CLS’ TRANBERG® Thermal Therapy System for high-precision, minimally invasive interventions.

RhoVac AB announces that the company’s clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002, is expected to be further delayed due to the prevailing Covid-19 pandemic.